Cerevel Therapeutics Holdings, Inc. (CERE)
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.
Address
222 JACOBS STREET
CAMBRIDGE, MA 02141
Founded
2018
Number of Employees
334
Website
http://www.cerevel.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)